News 2011 › 2011-01-26
Nexstim on a roll
Non-invasive brain diagnostic and therapy technology pioneer, Nexstim has recently raised valuable additional equity financing for its business – adding Lundbeckfond Ventures of Denmark and the Ilmarinen Mutual Pension Insurance Company to the company’s previous venture capital investors: HealthCap and LSP (Life Sciences Partners), Sitra, and Finnish Industry Investment.
The new financing will enable Nexstim to significantly expand its sales and marketing activities in Europe and take full advantage of its recent FDA clearance for marketing in the US.
Nexstim also intends accelerating development of next-generation solutions for non-invasive neurotherapy in stroke and other neurological conditions that are largely unmet using conventional technologies.
Founded in 2000, Nexstim is a specialist in Navigated Brain Stimulation (NBS), a non-invasive, image-guided transcranial magnetic stimulation (TMS) technique for brain diagnostics and therapy. The Nexstim NBS System is rapidly becoming the new standard for preoperative functional brain mapping prior to neurosurgery on tumours or to treat epilepsy – and is the only direct, non-invasive cortical mapping device cleared for sale in both the US and Europe.